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Background: The European Respiratory Society recently published an important statement reviewing available
evidence on diagnosis and treatment of lung disease associated to alpha-1 antitrypsin deficiency (AATD). Several
issues on this topic still remain unresolved and subject of interpretation according to different standard procedures
and healthcare systems worldwide. The purpose of this commentary is to offer a critical contribution to most of
these controversial issues in light of an Italian perspective for the management of this disease.
Main body: The clinical spectrum of AATD lung disease might include different manifestations and the traditional
paradigm of a younger emphysematous patient has been revealing insufficient. Targeting with appropriate testing
only COPD patients might be considered a limited approach leading to underestimation of the real prevalence of
the disease. Several reports have suggested the association between AATD and other chronic respiratory
conditions, as asthma and bronchiectasis. A deeper evaluation of clinical, radiological, microbiological and
functional variables is, therefore, needed in order to investigate different phenotypes in AATD patients. In addition,
a new line of translational research in AATD might focus on the development of personalized therapeutic regimens
taking into account the patient clinical profile and needs.
Conclusions: Over the past years, AATD has been interpreted as a common mechanism of inflammatory
disequilibrium and tissue damage across different conditions. Future research is gradually pointing toward this new
paradigm by expanding the evidence of the role of AAT as a potent immunomodulatory and anti-inflammatory
drug in conditions different from pulmonary emphysema.
Keywords: Alpha-1 antitrypsin deficiency, Bronchiectasis, COPD, ERS statement* Correspondence: stefano.aliberti@unimi.it
1Department of Pathophysiology and Transplantation, University of Milano;
Internal Medicine Department, Respiratory Unit and Adult Cystic Fibrosis
Center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano,
Italy
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Gramegna et al. Multidisciplinary Respiratory Medicine  (2018) 13:39 Page 2 of 10Background
Alpha-1 Antitrypsin Deficiency (AATD) is the most
common hereditary disorder in adults [1]. There are sev-
eral mutations of the SERPINA1 gene, encoding for
AAT which is the most prevalent protease inhibitor in
serum, that can cause disease. Despite its name, the
major biological role of AAT is to inhibit neutrophil
elastase (NE), a proteolytic enzyme targeting elastin and
other basal membrane and matrix components [2].
AATD is inherited as an autosomal codominant disease
and more than 100 genetic variants have been described
so far and the homozigous genotype for Z allele (PI*ZZ)
accounts for the vast majority of clinically recognized se-
vere deficiency [3]. Severe AATD is a multi-organ dis-
order that might be associated with a large spectrum of
lung disease with resulting FEV1 decline and impairment
in gas transfer. Although the clinical course is not fully
explained, patients with AATD have increased mortality,
especially in the presence of smoking and severe FEV1
impairment [4–6]. Over the past years, a few random-
ized clinical trials have reported augmentation therapy
with intravenous purified human AAT concentrate to
improve AAT blood levels and reduce FEV1 or, as re-
cently described, lung density decline in severe AATD
patients [1, 7–9].
In 2017 the European Respiratory Society (ERS) pub-
lished a renewed statement on diagnosis and treatment
of pulmonary disease in AATD [10]. This document was
developed by a task force including experts in AATD pa-
tient management, basic and clinical researchers and
one methodologist. The previous 2003 ATS/ERS state-
ment was used as a starting point [1]. The panelists ad-
dressed the most relevant issues on diagnosis, clinical
management and treatment of pulmonary disease in
AATD patients by the formulation of a priori questions
and answered through a comprehensive search of litera-
ture. The search was limited to severe AATD cohorts
(i.e. homozygous Z or null genotype and Z/null geno-
type). A GRADE approach to degree recommendations
according to the quality of evidences was not adopted. A
summary of ERS statements is reported in Table 1.
The purpose of this commentary is to offer a contribu-
tion to most controversial issues regarding pulmonary
disease associated with AATD. In presenting these argu-
ments, three main topics will be addressed, including 1)
the limitation of the current definition of AATD lung
disease; 2) the need of broader testing and improvement
of AATD awareness among physicians taking care of
chronic respiratory diseases; 3) new paradigm and per-
spectives in AATD future research.
Heterogeneity of AATD associated lung disease
In the attempt to give a definition of associated lung dis-
ease, the task force attributed a wide degree ofheterogeneity to pulmonary involvement in AATD.
However, in their considerations authors relied on the
classical phenotype of a patient with onset of COPD at a
younger age and more likely to have basal panlobular
emphysema than usual COPD patients [10]. This is, in
our view, a crucial point.
AATD pulmonary involvement might include emphy-
sema with severe functional and radiological impairment
as well as different pulmonary pictures or, even, normal
chest CT scan [11]. In a series of PI*ZZ patients, Gishen
analyzed 165 chest radiographs and reported emphy-
sema pattern only in 20% of patients, while 15% ap-
peared completely normal [12]. DeMeo and colleagues
demonstrated in a population of 378 patients with severe
AATD (PI*ZZ) that variability in FEV1 was huge and did
not relate to smoking status or younger age. Thus, some
smokers had preserved lung function, while some
non-smokers had lower FEV1 [13]. These data suggest
that neither FEV1 nor chest radiology are sufficient to
rise clinical suspicion of AATD in daily practice. As a
consequence, most of severe AATD patients might not
be still identified and case finding only among COPD
patients is not sufficient. In addition, the unusual associ-
ation between most common deficitary alleles in AATD
and idiopathic pulmonary fibrosis (IPF), or combined
pulmonary fibrosis and emphysema (CPFE) have also
been described [14, 15].
Targeting with appropriate testing only those patients
with classic AATD clinical presentation might be con-
sidered a limited approach leading to underestimation of
the real prevalence of the disease. In view of the extreme
variety of this condition, the paradigm of pure emphyse-
matous patients has gradually changed by the under-
standing that the clinical spectrum of AATD lung
disease might include different phenotypes (Fig. 1).
AATD and asthma
A review explored the association and overlap between
AATD and asthma [16]. Subsequent to the first descrip-
tions of AATD patients, Makino and Black reported case
series of emphysematous patients with clinical feature of
airway reactivity and wheezing [17, 18]. In the next
years, several reports ranged the prevalence of asthma in
AATD population from 4 to 34% [19–22]. In the
National Heart, Lung and Blood Institute’s Registry of
AAT Deficient Individuals (NHLBI), a network of 37
centers across USA and Canada for a total of 1219 sub-
jects, 55% of patients reported a significant response to
bronchodilation, while concomitant asthma and respira-
tory allergy were reported in 31% and 23% of cases, re-
spectively [23, 24]. On this basis, in 1997 the WHO
recommended that all patients with COPD and
adult-onset asthma should be screened for AATD [25].
A recent study conducted through the Alpha-1
Table 1 Summary of European Respiratory Society statements on diagnosis, clinical management and treatment of pulmonary
disease in α1-antitrypsin deficiency [10]
AATD and lung disease • The clinical impact of AATD is highly variable. Heterogeneity in lung disease is only partly explained by
exposure to known risk factors, such as cigarette smoke.
• Lung disease in AATD generally presents at a younger age than “usual” COPD and may be misdiagnosed
as asthma.
• Although the patients’ clinical phenotype may vary they are more likely to have basal emphysema than
patients with usual COPD.
• The WHO recommends all patients with a diagnosis of COPD or adult-onset asthma should be tested for
AATD.
Laboratory diagnosis and hierarchy
of testing
• The quantitative determination of AAT levels in blood is a crucial first test to identify AATD. Quantitative
deficiency must be supported by qualitative tests to identify the genetic mutation(s) causing AATD.
• Protein phenotyping by isoelectric focusing identifies variants where AAT is present in the sample
including the rarer variants F, I and P etc.
• Genotyping allows a rapid and precise identification/exclusion of S and Z alleles and other variants,
where specific primers are available.
• Gene sequencing remains necessary for those cases where a null variant or a deficient variant other than
Z or S is suspected.
• Testing of relatives of identified patients should be considered after appropriate counselling.
• Genetic testing should be carried out only after informed consent is given and in accordance with the
relevant guidelines and legislation.
Lung disease progression in AATD • Annual measurement of lung function including post-bronchodilator FEV1 and gas transfer provides
information about disease progression.
• Lung densitometry, as performed in observational cohort studies and randomised clinical trials is the most
sensitive measure of emphysema progression.
• The correlation between change in lung density and any short-term change in measures of pulmonary
function is weak. However, in the longer term, CT lung density decline correlates with reduction in FEV1
and health status.
• The role of CT in the follow-up of patients in routine clinical practice requires further validation.
The risk of lung disease in heterozygotes • Never-smoking PiMZ subjects do not have an increased risk for COPD.
• Smoking PiMZ and PiSZ subjects have an increased risk of COPD compared to smoking PiMM subjects.
• The role of other heterozygotes remains unknown due to their rarity and potential ascertainment bias from
measuring AAT in unusual cases of lung or liver disease.
Role and benefits of screening • Most screening studies have been biased as they did not involve random population samples.
• Population-based screening studies provide less biased prevalence estimates of specific AATD protein and
clinical phenotypes as well as valuable insights into the natural history of AATD.
• Neonatal screening has been shown to be effective in reducing the smoking rates for 18–20-year-olds
compared to age-matched individuals.
• Screening may have negative psychological effects on parents and on mother–child bonding. However,
these negative effects can be addressed by comprehensive genetic counselling and care provision at
centres of excellence for AATD.
Augmentation therapy for AATD • Several randomised clinical trials in severe AATD have shown intravenous augmentation therapy to reduce
the progression of emphysema as assessed by CT densitometry.
• There is no evidence to support efficacy of AAT augmentation therapy in PiSZ, PiMZ or current smokers of
any protein phenotype.
• Clinical trials have used fixed doses of AAT determined by body weight. Whether individualising dosage
based on trough levels for each patient has any benefit requires confirmation.
Lung volume reduction surgery
in AATD
• Surgical volume reduction and EBV placement may be considered in selected patients with AATD, but
further studies are needed to confirm the role of such therapies.
• The optimal results of these techniques are obtained when a careful appraisal of risks and benefits are
performed by a multidisciplinary team experienced in LVR and AATD.
Lung transplantation for emphysema
associated with AATD
• The survival benefit of lung transplant in AATD patients is not clear.
• In general, patients with AATD have improved quality of life following lung transplantation.
• Referral timing, rate of decline in lung function, health status and social support differ from patient to
patient, and will have an influence on the evaluation for transplant.
• The role of post-transplant augmentation therapy in particular needs to be explored.
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Table 1 Summary of European Respiratory Society statements on diagnosis, clinical management and treatment of pulmonary
disease in α1-antitrypsin deficiency [10] (Continued)
New lines of research in AATD • According to the European Council, management of patients with AATD should be supervised by reference
centres of excellence at a national or regional level.
• The systematic collection of data concerning clinical characteristics and natural history of patients with AATD in
national and international registries will enhance knowledge about the evolution of this disease and its optimal
management.
• For many AATD individuals a respiratory service is the first point of diagnosis. The operational pathway includes
varying assessments and follow-up depending on personalising the patients’ risk and defining the respiratory
phenotype. Links to multidisciplinary teams will ensure the best quality of care.
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with severe deficiency, confirmed that clinical manifesta-
tions of uncontrolled asthma or asthma with fixed ob-
struction are frequent in AATD; however, among the
34% participants undergoing allergological evaluation,
only 5% were diagnosed with AATD [26].
Although current literature is controversial about the
prevalence of AAT deficiency alleles in asthmatic popu-
lation, AATD was reported in 2.4% of patients with
poorly controlled asthma with 10.5% being a carrier of a
deficiency mutation [27, 28]. This contributed to the in-
terpretation that AATD itself might predispose to airway
hyper-reactivity and participate to asthma pathophysi-
ology. While the underlying biological mechanism is not
understood, data from basic research have in fact sug-
gested that AAT has also immunomodulatory functions
and might affect eosinophilic cells [29].
Finally, AATD patients with concomitant asthma have
worse prognosis. Bronchodilator response has been asso-
ciated with greater FEV1 decline and poorer clinical out-
comes [13, 24, 30]. From the clinician’s point of view,
improving diagnosis in this population is fundamental to
optimize clinical management and further clinical trials
are needed to investigate patients’ response to available
treatments.Fig. 1 AATD might be interpreted as a common mechanism with
different clinical manifestations and frequent overlap among chronic
respiratory disordersAATD and bronchiectasis
Several reports have suggested the association between
AATD and bronchiectasis [21, 31, 32]. In order to address
the prevalence and clinical impact of bronchiectasis in this
population, Parr and Stockley retrospectively studied 74
subjects with severe AATD who had received a HRCT
scan in the time period 1995–2002. They reported an un-
expectedly high prevalence of bronchiectatic changes in
almost all patients (70/74 subjects, 94.6%) without regard
to clinical manifestations. If criteria for clinically signifi-
cant bronchiectasis were applied, i.e. chronic cough with
sputum production in association with bronchial dilation
in at least four bronchial segments, bronchiectasis oc-
curred in 27% of study population [33].
The concept of association between bronchiectasis and
AATD is also supported by data coming from a large
targeted screening program for AATD in Germany.
Greulich and colleagues analyzed 18,638 testing kits and
identified 1835 patients with severe AATD (9.82% of the
tested population). Along with emphysema and COPD,
bronchiectasis demonstrated to be a strong predictor for
PI*ZZ genotype suggesting the implementation of
screening in this emerging population [34].
From a different perspective, among physicians taking
care of bronchiectasis AATD has been recognized as a
cause of bronchiectasis and a causal link has been hy-
pothesized. The common origin of airway disease in
AATD might be explained by the disequilibrium be-
tween neutrophilic inflammation and protease inhibi-
tors, thus resulting in bronchial connective tissue
damage [35]. In addition, AAT has been demonstrated
to act as an anti-inflammatory mediator by the inhib-
ition of TNF-α and IL-1β levels in mononuclear cell cul-
tures [36]. However, whether bronchiectasis comes from
a primary mechanism of the disease or is the result of
recurrent respiratory infection is still matter of debate.
In 2015 Lonni and co-authors conducted an extensive
analysis of seven cohorts of adult outpatients with bron-
chiectasis prospectively enrolled between 2009 and 2013
in different countries across Europe [37]. All patients
underwent the same etiological workup as suggested by
BTS guidelines, including quantitative analysis of AAT
in plasma in those subjects with radiological
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cause of bronchiectasis in a total of 8 (0.6%) of popula-
tion. This result is consistent with those reported by a
comprehensive review performed to identify papers
reporting the underlying etiologies of published cohorts;
AATD was identified as a cause of bronchiectasis in 36
(0.4%) out of 8608 patients [38]. The vast majority of
those patients came from Europe (n = 23) and Northern
America (n = 12), suggesting that only a portion of stud-
ies performed in developed countries had provided some
sort of testing on AATD.
Over the past decade, different national and international
registries have been set up to evaluate the real-life charac-
teristics of patients with different respiratory diseases, in-
cluding bronchiectasis, severe asthma and NTM [39]
https://www.registroirene.it/it/user [40]. Looking into the
Italian situation, the first data from the Italian Registry on
Adult Bronchiectasis (IRIDE) have been presented at the
2nd World Bronchiectasis Conference http://www.world
-bronchiectasis-conference.org/wp-content/uploads/2017/
07/AbstractBook_WEB.pdf. Among 522 adults with bron-
chiectasis (to May 2017) the diagnosis of AATD was less
than 1% of population.
Although this amount of data documented the role of
AATD as an underlying etiology of bronchiectasis, it is
possible to presume that a majority of patients never re-
ceived AAT testing. In 2014 the Italian Respiratory Soci-
ety (IRS/SIP) conducted a national audit on adult
patients with bronchiectasis attending secondary care
clinics in Italy [41]. The audit analysed adherence among
physicians to quality standards as suggested by the Brit-
ish Thoracic Society. To date, this represents the only
testing of quality standards for bronchiectasis in Italy. In
regard to etiological screening of bronchiectasis, only
8.2% of patients were tested for AATD. As a result, it is
likely to hypothesize that estimation of AATD preva-
lence in bronchiectasis population is poor.
Notably, both in the European analysis as well as in the
Italian report COPD was among the three most prevalent
cause of bronchiectasis with 15% and 7.8% of population,
respectively [37] http://www.world-bronchiectasis-confer-
ence.org/wp-content/uploads/2017/07/AbstractBook_WE
B.pdf. The association between COPD and bronchiectasis
might represent a distinct phenotype in patients charac-
terized by chronic respiratory infections, more severe air-
way inflammatory pattern and frequent pulmonary
exacerbations [42]. However, the question if COPD and
bronchiectasis co-exist as two indipendent diseases or one
is the cause of the other still remains unanswered.
AATD and NTM
Nontuberculous mycobacteria (NTM) are a large num-
ber of pathogenic and non-pathogenic mycobacterial
species different than m. tubercolosis complex. Recentreports demonstrated an increasing role of NTM in pa-
tients with underlying respiratory disorders, as bronchi-
ectasis and COPD [43–45]. However, susceptibility to
the development of NTM pulmonary disease is different
among patients and AATD has been postulated as a po-
tential predisposing factor. In a cohort of 100 patients
with NTM pulmonary disease, AAT genetic variants
were reported in 27% of cases, which is 1.6 times than
estimated prevalence in general population. Most of
those patients showed Pi*MS and Pi*MZ heterozigosity
and no sign of pulmonary emphysema. In addition, AAT
has also been demonstrated to impair M. abscessus
phagocytosis by human macrophages, thus forbidding
NTM the ideal intracellular milieu [46]. Thus, in consid-
eration of its pleiotrophic anti-inflammatory and immu-
nomodulatory effects, AATD might increase patient
vulnerability to NTM both directly and through bron-
chiectasis development.
Clinical implications: The role and benefits of
screening
Since a majority of AATD patients is still unidentified
and delays in making the correct diagnosis are common,
structured programs of AAT testing have been dis-
cussed. ERS statement discussed the role and benefits of
screening for AATD and summarized current evidence
(Table 1). Most of population screening of adults in the
past has been limited to specific groups, as blood do-
nors, with resulting esteem of prevalence biased by se-
lection [10]. A more accurate evaluation came from
programs including random population samples [41, 42].
A large population-based screening was performed in
Ireland on 3000 subjects and identified 42 ZZ, 44 SZ
and 430 MZ individuals, a prevalence estimation greater
than previously thought [47]. Another experience came
from Poland where 859 adult subjects (mean age
49.5 years, range 20–90) were screened with resulting fre-
quencies of PI*S and PI*Z equal to 17.5 per 1000 and 10.5
per 1000, respectively. Therefore, the estimated prevalence
of AATD was high enough to consider implementation of
a large-scale screening program [48]. However, the ERS
statement reported that no RCT investigated efficacy and
effectiveness of AATD screening programs and evidence
for this approach is currently poor [10].
This bundle of evidence has been evaluated differently
across guidelines regarding chronic respiratory condition
that might be related to AATD. Although AATD is
strongly associated to the development of COPD, The
Global Initiative for Chronic Obstructive Lung Disease
(GOLD) document edited in 2018 mentioned AATD in
only two occasions. First, as a known genetic risk factor
for COPD and an example of gene-environment inter-
action; second, as a step in COPD assessment that
WHO guidelines recommended to screen once in all
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with high AATD prevalence [49]. On the contrary, Glo-
bal Initiative for Asthma Management and Prevention
(GINA) document has only one mention of AATD as a
possible differential diagnosis in patient with suspected
asthma in presence of family history of emphysema and
aged between 12 and 39 years. Notably, no indication
for AATD testing in asthmatic patients can be found in
this document [50].
In regard to bronchiectasis, the scenario is more com-
plex since international guidelines did not exist until re-
cently. A few national guidelines did not recommend
routine AATD testing unless the radiological investiga-
tions suggest basal emphysema [51, 52]. Otherwise, guide-
lines from Pulmonology Portuguese Society included AAT
quantitative test in the minimum bundle of etiological
screening for all patients with bronchiectasis [53]. In 2017
the ERS published the first international standards of care
for bronchiectasis in adult patients [54]. This document
suggests providing AATD testing only in the presence of
basal emphysema or early onset airway obstruction. A
comprehensive summary of recommendations for AATD
testing in different documents is provided in Table 2.
This lack of common ground in testing AAT across re-
spiratory diseases needs further considerations. Identify-
ing AATD is fundamental in view of clinical, social and
psychological consequences in target population. First,
AATD is a systemic disease with extra-respiratory clin-
ical manifestations that might benefit from a specific
management with positive impact on clinical outcomes
and patients’ quality of life. AATD patients should have
access to reference centers, that are able to provide the
best standard of care and contribute to clinical data net-
working. Furthermore, patients affected by a rare disease
might benefit from free care or proper health insurance
issues across different jurisdictions. From a psychological
perspective, AATD is both a genetic disease with in-
creased risk of affected children and a chronic condition
with possible impact on family planning and patients’ lifeTable 2 A comprehensive summary of indications for AATD testing
respiratory disease
Document Disease
Global strategy for prevention, diagnosis and management
of COPD, 2018 [49]
COPD
Global strategy for asthma management and prevention,
2018 [50]
Asthma
European Respiratory Society, 2017 [54] Bronchiecta
Pulmonology Portuguese Society Bronchiectasis
Study Group, 2018 [53]
Bronchiecta
Thoracic Society of Australia and New Zealand, 2015 [62] Bronchiecta
British Thoracic Society, 2010 [51] Bronchiecta
Normativa SEPAR, 2008 [52] Bronchiectapriorities. In this respect, AATD patients should be pro-
vided with proper genetic counseling and support.Different perspectives of AATD definition and indications
for augmentation therapy
The definition of AATD might rise some controver-
sial among physicians in respiratory care. Three dif-
ferent scenarios are possible: 1) deficiency as the
condition of lower-than-normal AAT levels in blood;
2) deficiency as the result of mutations affecting SER-
PINA gene; 3) deficiency as the indication for aug-
mentation therapy for AATD.
AAT deficiency as the condition of lower AAT levels
in blood. This definition is focused on the quantita-
tive determination of blood levels and represent the
widest interpretation of deficient status. Currently
nephelometry and immunoturbidimetric assay are the
most widely employed techniques; in this regard, ERS
statement reported a comprehensive list of laboratory
methodologies used in central laboratories across
Europe [10].AAT deficiency as the result of a genetic disease
As suggested by ERS statement, abnormal quantitative
measurements of AAT levels in blood must be sup-
ported by a qualitative test detecting SERPINA gene mu-
tations on both copies of the gene [7]. The normal allele,
designated as M, is present in 85–90% of population,
while the prevalent deficient alleles are designated as S
and Z [1]. As a consequence, the most common geno-
types result from the combination of these allelic forms:
the homozygous genotype Pi*MM (wild-type), the het-
erozygous Pi*MZ and Pi*MS and the semi-deficient or
deficient genotypes Pi*SZ, Pi*SS and Pi*ZZ. Besides defi-
cient alleles S and Z, about 50 other uncommon muta-
tions have been described, including (null) allele and
other rare variants [55].across documents for the clinical management of chronic
Indications for AATD testing
All patients with a diagnosis of COPD, especially in areas with
high AATD prevalence
No indication for AATD testing
sis Patients with basal emphysema or early onset airflow obstruction
sis All patients with a diagnosis of BE
sis No indication for AATD testing
sis Patients with basal emphysema.
sis Patients with emphysema and /or liver disease
Fig. 2 The protease/anti-protease balance in healthy subjects (a),
AATD patients (b) and bronchiectasis patients (c). Definitions.
AAT = alpha-1 antitrypsin deficiency; NE = neutrophil elastase;
LLN = lower limit of normality
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therapy
Intravenous infusion of alpha1-proteinase inhibitor, prepared
from pooled human plasma of normal donors, has the bio-
chemical goal to raise and maintain serum AAT levels above
the protective threshold and clinical goals to slow the pro-
gression of emphysema, reduce number of exacerbations
and enhance the duration and quality of life. [56, 57].
Up to now augmentation therapy has been approved
only for commercial use in adults with severe AAT
deficiency-related pulmonary emphysema and a number
of AAT preparations are currently available in various
markets [56].
Evidence that augmentation therapy brings benefits
(eg, slowed rate of FEV1, decline and decreased
mortality) is stronger for individuals with moderate
obstructive pulmonary impairment (eg, FEV1 35–
60% predicted) than for those with severe airflow
obstruction [57].
Implications for future research
In consideration of the bundle of evidence showing a
causative role of AATD in bronchiectasis, a deeper
evaluation of clinical, radiological, microbiological and
functional variables should be applied in order to in-
vestigate different phenotypes in AATD patients. The
identification of a distinct bronchiectasis phenotype
might be useful for a better understanding of AATD
pathophysiology, as well as to improve personalized
approach towards sub-groups of patients that might
benefit from a focused treatment. A new generation
of RCTs is, therefore, needed to test efficacy of intra-
venous AAT augmentation therapy in patients with
combined bronchiectasis and severe AATD. At the
same time, new end-points for monitoring progres-
sion of lung disease and response to therapy in this
population ask to be explored.
In addition, decisions for starting the chronic augmenta-
tion therapy need to be made at this point on a risk/bene-
fit basis, as the lung destruction in emphysema is
irreversible and a new line of translational research in
AATD might focus on the development of personalized
therapeutic regimens taking into account the patient clin-
ical profile and needs [58]. In this light, investigating a
new role for augmentation therapy in patients with het-
erozygosity (PI*MZ, PI*MS) is urgently needed, especially
in the presence of other chronic respiratory conditions as
asthma or bronchiectasis. The rationale is that the
anti-protease activity provided by AAT, although present
in normal amounts, is finally compromised in patients
with chronic inflammatory disease, such as bronchiectasis,
due to the overwhelming NE inflammatory burden [2].
The condition would result in functional deficiency of
AAT (Fig. 2). This supports the idea of an individualizedapproach to augmentation therapy based, not only on the
genotype of patient, but also on a careful evaluation of ex-
pected benefits, risks and sanitary costs.
The use of AAT treatment in patients
other-than-PI*ZZ dates back decades and has been
already explored in cystic fibrosis (CF), a genetic sys-
temic disease characterized by massive neutrophilic in-
flammation on the lung epithelial surface. In 2007
Griese and colleagues performed a prospective uncon-
trolled study of 4-week inhaled AAT in a cohort of 52
patients with CF. The primary outcome of this study
was a reduction in NE activity, along with change in
neutrophils and pro-inflammatory cytokines on spu-
tum. Although results on pulmonary function were
controversial, the authors found a significant decrease
in all inflammatory markers measured during treatment
[59]. Similarly, two other studies showed reduction in
elastase activity in CF subjects following inhaled treat-
ment of AAT [60, 61]. However, a correlation with clin-
ical outcomes would require long-term multicentre
studies.
Table 3 A list of last decade clinical trials testing AAT safety and efficacy in conditions different from severe deficiency AAT
according to clinicaltrials.gov, last access 15 july 2018
Study Title Condition Phase Start Date Status
A proof-of-concept pilot trial of AAT for pre-emption of steroid refractory
acute GVDH
GVDH 2 2018 Recruiting
Multicenter trial of the effect of AAT on Islet Transplant engraftment and
durability after Renal Transplant
Diabetes Mellitus, Type 1 2 2017 Recruiting
Anti-inflammatory therapy to improve outcomes in patients with
Chronic Pancreatitis undergoing Total Pancreatectomy Islet
Autotransplantation
Chronic Pancreatitis;
Diabetes Mellitus, Type 1
4 2016 Recruiting
AAT enhances islet autograft survival Chronic Pancreatitis 1–2 2016 Recruiting
A phase 2/3 clinical study to evaluate the safety and efficacy of AAT as an
add-on biopharmacotherapy to conventional steroid treatment in subjects
with acute GVDH with lower gastrointestinal involvement
GVDH 2–3 2016 Terminated
A proof-of-concept study evaluating the safety and efficacy of human
AAT treatment in first Lung Transplantation
Transplantation, Lung Rejection 2 2015 Active, not
recruiting
Improving single donor success rate in clinical islet using AAT Diabetes Mellitus, Type 1 1–2 2015 Active, not
recruiting
A multicenter, randomized, placebo-controlled study to evaluate the safety
and efficacy of a human plasma-derived AAT in subjects with new-onset
Type 1 Diabetes Mellitus
Diabetes Mellitus, Type 1 2 2014 Terminated
Single dose administration of AAT for the amelioration of organ injury
and post-operative bleeding in patients undergoing cardiac surgery with
cariopulmonary bypass
Post Cardiac Surgery Systemic
Inflammatory Response
1–2 2014 Unknown
Pilot study of AAT: a novel treatment to mitigate Neuromyelitis Optica
attacks
Neuromyelitis Optica 1 2014 Unknown
Long-term treatment safety, tolerability and efficacy of AAT in Type 1
Diabetes
Diabetes Mellitus, Type 1 2 2013 Completed
AAT to quench the acute inflammatory response in ST-segment elevation
Acute Myocardial Infarction
Acute Myocardial Infarction 1–2 2013 Completed
Phase 2 study to evaluate the efficacy and safety of human AAT in the
treatment of new onset Type 1 Diabetes
Diabetes Mellitus, Type 1 2 2013 Completed
Effects of Prolastin aerosol therapy on bacterial density in the airways of
patients with CF
Cystic Fibrosis 2 2013 Terminated
AAT in treating patients with acute GVDH GVDH 1–2 2012 Completed
Safety and tolerability of inhaled AAT once-a-day in patients with
Cystic Fibrosis
Cystic Fibrosis 2 2012 Completed
Safety and efficacy of AAT in HIV Disease HIV Disease 2–3 2012 Terminated
A pilot study of AAT in steroid refractory acute GVDH GVDH 2 2012 Active, not
recruiting
The effects of AAT on the progression of Type-1 Diabetes in subjects
with detectable C-peptide
Diabetes Mellitus, Type 1 1 2011 Completed
Proof-of-concept study of the safety, tolerability and efficacy of intravenous
AAT in Type 1 Diabetes
Diabetes Mellitus, Type 1 1–2 2011 Completed
Safety and efficacy of inhaled AAT in preventing Bronchiolitis Obliterable
Syndrome in Lung Transplant recipients
Transplantation, Lung Rejection 2 2011 Unknown
Safety and tolerability study of AAT inhalation solution in patients with
Cystic Fibrosis
Cystic Fibrosis 1 2011 Completed
Effects of intravenous AAT on preserving beta-cell function in new-onset
Type 1 Diabetes Mellitus
Diabetes Mellitus, Type 1 2 2010 Withdrawn
AAT alpha-1 antitrypsin, CF cystic fibrosis GVDH graft-versus-host disease, HIV human immunodeficiency virus
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During the last years AATD has been interpreted as a
common mechanism of inflammatory disequilibrium
and tissue damage among both chronic respiratorydiseases and extra-respiratory conditions. The final clinical
picture would, therefore, result of a complex and mostly
unknown interaction between genetic pattern and envir-
onmental factors. Future research is gradually pointing
Gramegna et al. Multidisciplinary Respiratory Medicine  (2018) 13:39 Page 9 of 10toward this new paradigm by expanding the evidence of
the role of AAT augmentation treatment as a potent im-
munomodulatory and anti-inflammatory drug for condi-
tions different from pulmonary emphysema (Table 3).
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